{"id":55894,"date":"2023-04-17T16:06:23","date_gmt":"2023-04-17T14:06:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/"},"modified":"2023-04-17T16:06:23","modified_gmt":"2023-04-17T14:06:23","slug":"recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/","title":{"rendered":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development"},"content":{"rendered":"
\n

\n\u2013 Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials \u2013<\/i><\/b><\/p>\n

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics<\/a>, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development. Dr. Matthews will oversee clinical development planning and strategy.<\/p>\n

<\/a><\/p>\n

\n\u201cWe are delighted to welcome Dr. Matthews to build and lead our clinical team,\u201d said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics. \u201cAs a pulmonary and immunology drug developer with extensive experience in human genetics and inhaled drug delivery, Dr. Matthews brings a unique perspective at a formative stage of our development. I look forward to working with him as we continue to advance our pipeline of next generation precision genetic medicines for people affected by rare diseases.\u201d<\/p>\n

\nDr. Matthews brings over twenty years of proven leadership in clinical trial design and drug development, and extensive patient care experience. He has significant expertise in rare pulmonary diseases and larger respiratory indications and was most recently at 23andMe, where he led their rare disease therapeutic strategy and provided leadership for drug development programs aimed at discovering novel genetic targets.<\/p>\n

\n\u201cWith its selective organ targeting (SORT) lipid nanoparticle (LNP) technology, ReCode is pioneering a novel approach to solving one of the most significant challenges in the delivery of genetic medicines for rare diseases – an area I am incredibly passionate about,\u201d said Dr. Matthews. \u201cI look forward to playing a pivotal role in advancing ReCode\u2019s lead candidates for primary ciliary dyskinesia and cystic fibrosis into the clinic this year, and ultimately, building a clinical pipeline aimed at unlocking the full potential of genetic medicines.\u201d<\/p>\n

\nPrior to 23andMe, Dr. Matthews served as vice president of clinical development at Aimmune Therapeutics supporting both late and early-stage programs. He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director. Before Genentech, Dr. Matthews held positions of increasing responsibility at Novartis Pharmaceuticals and was a clinical scientist in the department of early development for respiratory and inflammation products at GlaxoSmithKline, where he worked on a novel inhaled steroid among other molecules.<\/p>\n

\nDr. Matthews trained in pulmonary medicine at the Royal Brompton Hospital and the Lane Fox Respiratory Unit, St Thomas\u2019 Hospital, London. He earned his Ph.D. in respiratory clinical pharmacology from Imperial College London. He is a member of the Unbiased BIOmarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) program and serves as executive director of RASP-UK, a large-scale research project that aims to target treatments effectively in patients with severe asthma.<\/p>\n

\nAbout ReCode Therapeutics<\/b><\/p>\n

\nReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics. ReCode\u2019s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode\u2019s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode\u2019s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech\u2019s \u201cFierce 15\u201d as one of the most promising early-stage biotechnology companies in the industry and was described by Nature as one of the \u201cSeven Technologies to Watch in 2022\u201d for its SORT LNP platform. For more information, visit www.recodetx.com<\/a> and follow us on Twitter @ReCodeTx<\/a> and on LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Sarah McCabe
\n
Stern IR
\n
Sarah.McCabe@sternir.com<\/a>
IR@recodetx.com<\/a><\/p>\n

\nMedia Contact:<\/b>
Tara Cooper
\n
The Grace Communication Group
\n
tara@gracegroup.us<\/a>
650-303-7306<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials \u2013 MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55894","6":"format-standard","7":"category-industry"},"yoast_head":"\nReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials \u2013 MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T14:06:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development\",\"datePublished\":\"2023-04-17T14:06:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/\"},\"wordCount\":683,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005352\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/\",\"name\":\"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005352\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"datePublished\":\"2023-04-17T14:06:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005352\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230417005352\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/","og_locale":"en_US","og_type":"article","og_title":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend","og_description":"\u2013 Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials \u2013 MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-17T14:06:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development","datePublished":"2023-04-17T14:06:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/"},"wordCount":683,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/","url":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/","name":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","datePublished":"2023-04-17T14:06:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230417005352\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55894"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55894\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}